Table 1.
Description of study subjects by vaccination status.
| Variable | Unvaccinated | Partially vaccinated | Fully vaccinated inactive vaccine | Fully vaccinated Adenovirus 5 vectored vaccine | Total |
|---|---|---|---|---|---|
| Clinical outcome | |||||
| Uninfected | 58(87.8) | 6(85.7) | 320(96.7) | 268(95.0) | 652(95.0) |
| Asymptomatic | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
| Mild | 3(4.6) | 0(0) | 5(1.5) | 7(2.5) | 15(2.2) |
| Moderate | 3(4.6) | 1(14.3) | 6(1.8) | 7(2.5) | 17(2.4) |
| Severe | 1(1.5) | 0(0) | 0(0) | 0(0) | 1(0.2) |
| Critical | 1(1.5) | 0(0) | 0(0) | 0(0) | 1(0.2) |
| Sex | |||||
| Male | 29(43.9) | 5(71.4) | 267(80.7) | 180(63.8) | 481(70.1) |
| Female | 37(56.1) | 2(28.6) | 64(19.3) | 102(36.2) | 205(29.9) |
| Age group (years) | |||||
| 18–59 | 52(78.8) | 6(85.7) | 325(98.2) | 268(95.0) | 651(94.9) |
| ≥60 | 14(21.2) | 1(14.3) | 6(1.8) | 14(5.0) | 35(5.1) |
| Vaccine history | |||||
| unvaccinated | 66(100) | NA | NA | NA | 66(100) |
| One dose | |||||
| Corona Vac | NA | 2(40) | NA | NA | 2(0.7) |
| BBIBP-CorV | NA | 1(20) | NA | NA | 1(0.3) |
| Ad5-nCoV | NA | 2(40) | NA | 282(100) | 284(99.0) |
| Two doses | |||||
| Corona Vac | NA | 0(0) | 170(51.4) | NA | 170(51.1) |
| BBIBP-CorV | NA | 2(100) | 92(27.8) | NA | 94(28.2) |
| CoronaVac and BBIBP-CorV* | NA | 0(0) | 69(20.8) | NA | 69(20.7) |
| Total | 66(100) | 7(100) | 331(100) | 282(100) | 686(100) |
*
Means a dose of BBIBP-CorV followed by a dose of CoronaVac or vice versa.